Why the study?
The study aimed to evaluate the association between H-FABP and cardiovascular events and determine its diagnostic accuracy and clinical relevance as a biomarker, especially in the initial phases of AMI and ACS.
Does H-FABP measurement improve the diagnosis and risk prediction of cardiovascular events in patients presenting with suspected cardiac events?
Does H-FABP measurement improve the diagnosis and risk prediction of cardiovascular events in patients presenting with suspected cardiac events?
While H-FABP exhibits high sensitivity for detecting early myocardial injury, current evidence does not support its routine use in the initial evaluation of suspected acute coronary syndrome.
Insufficient evidence supports routine H-FABP use for AMI/ACS despite diagnostic performance; prospective validation trials needed.
The research aimed to evaluate the association between heart-type fatty acid binding protein (H-FABP) and cardiovascular events. We systematically reviewed research that has been conducted to assess this relationship, aiming to determine how useful H-FABP could be as a biomarker for cardiovascular diseases, especially in the initial phases of acute myocardial infarction (AMI) and acute coronary syndrome (ACS). Our goal was to validate its diagnostic accuracy and clinical relevance. We systematically searched through PubMed, Web of Science, and Google Scholar databases to find pertinent publications related to cardiovascular diseases and H-FABP, using various permutations, abbreviations, and language variations of MeSH keywords. The final analysis included 12 studies in total. The final study comprised twelve studies, and it was concluded that H-FABP demonstrated high sensitivity (64.3-91.5) and specificity (73-100) for diagnosing Acute Myocardial Infarction (AMI) and Acute Coronary Syndrome (ACS), especially within the first hours of symptom onset. H-FABP demonstrates potential in enhancing the overall diagnostic accuracy during the initial hours following the manifestation of symptoms. However, the existing data do not provide sufficient evidence to recommend the regular utilization of H-FABP as a preliminary risk assessment approach in individuals who present with suspected cardiac events. Additional investigations, with well-defined prospective cohorts, are needed to validate the results observed.
No takes yet. Share an insight, caveat, or question.
Venu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: